The Food & Drug Administration's approval of AtriCure Inc.'s AtriClip system could be a boon not only for heart patients, but investors, too.
By Mary Vanac
Shares of West Chester, Ohio-based AtriCure Inc. (NASDAQ:ATRC) rose more than 20 percent Tuesday, a day after the Food & Drug Administration approved the company's AtriClip system for sale in the United States.
AtriCure shares rose as high as $7.20, ending the day up $1.07 at $6.30. More than 1 million AtriCure shares traded hands. That's 26 times as many shares than traded on any day in the last three months.
InspireMD presents new 6 month follow-up data showing better survival rates for its MGuard stent
Symbios Medical Products recalls 2 years' worth of its GoPump systems and GOBlock kits after...
Covidien's MicroStream MicroPod respiratory monitoring module hits the shelves
The newly unveiled iteration of the Microsoft Xbox One's Kinect camera demonstrates the ability to...
If you read nothing else today, make sure you're still in the know with MassDevice +3.